Fennec Pharmaceuticals (FENC) Operating Expenses (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Operating Expenses data on file, last reported at $16.3 million in Q4 2025.

• Quarterly Operating Expenses rose 84.34% year-over-year to $16.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.9 million (up 13.24% YoY) and the FY2025 annual result came in at $50.9 million, up 13.24% from the prior year.
• Operating Expenses rose to $16.3 million in Q4 2025, from $12.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $16.3 million in Q4 2025 to a low of -$5.0 million in Q2 2022.
• A 5-year average of $8.1 million and a median of $7.9 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses sank 227.78% — and 2023, when it jumped 259.53%.
• Tracing FENC's Operating Expenses over 5 years: stood at $4.2 million in 2021, then soared by 80.27% to $7.6 million in 2022, then surged by 52.33% to $11.6 million in 2023, then slipped by 23.32% to $8.9 million in 2024, then surged by 84.34% to $16.3 million in 2025.
• The last three Operating Expenses figures came in at $16.3 million (Q4 2025), $12.7 million (Q3 2025), and $12.4 million (Q2 2025), per Business Quant data.